Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Maxcyte Inc (NQ: MXCT ) 3.580 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Maxcyte Inc < Previous 1 2 3 4 5 Next > MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance November 06, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Two Upcoming Investor Conferences October 31, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Appoints Cynthia Collins to its Board of Directors October 15, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Earnings Preview March 11, 2024 Via Benzinga MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 October 11, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer October 10, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference September 05, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases September 16, 2024 Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology From MaxCyte, Inc Via GlobeNewswire MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance August 06, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 July 09, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference May 29, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development May 22, 2024 Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... From MaxCyte, Inc Via GlobeNewswire Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session May 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session May 08, 2024 Via Benzinga Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday May 08, 2024 Via Benzinga MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance May 07, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 April 10, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) April 02, 2024 Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs From MaxCyte, Inc Via GlobeNewswire Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket March 20, 2024 Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. Via Benzinga Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session March 20, 2024 U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. Via Benzinga Topics Stocks Exposures US Equities NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday March 13, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session March 13, 2024 U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session March 12, 2024 Via Benzinga MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance March 12, 2024 From MaxCyte, Inc Via GlobeNewswire Earnings Scheduled For March 12, 2024 March 12, 2024 Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. Via Benzinga MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results March 04, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences February 09, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers January 30, 2024 Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers From MaxCyte, Inc Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
